A 68-year-old man with a history of calcific aortic stenosis presents to the cardiology clinic. Transthoracic echocardiography is performed, and the Doppler assessment reveals the parameter marked **C** in the diagram to be 0.85 cm². He is currently asymptomatic with normal left ventricular ejection fraction. Which of the following is the most appropriate management strategy at this time?

Explanation

## Why "Serial echocardiographic surveillance every 6–12 months with stress testing if symptoms develop" is right The parameter marked **C** (AVA < 1.0 cm²) defines severe aortic stenosis by echocardiographic criteria. However, this patient is **asymptomatic** with preserved ejection fraction. According to Harrison 21e and ESC Valve Guidelines 2021, asymptomatic severe AS is managed conservatively with regular surveillance (every 6–12 months) and stress testing. Surgical intervention is reserved for asymptomatic patients who develop symptoms, demonstrate declining LVEF, show rapid progression, or have additional high-risk markers (AVA < 0.6 cm², mean gradient > 80 mmHg, or peak velocity > 5 m/s). This strategy balances the natural history of AS with the risks of early surgical intervention in asymptomatic patients. ## Why each distractor is wrong - **Immediate surgical aortic valve replacement regardless of symptoms**: Surgery is indicated for **symptomatic** severe AS (Class I), not asymptomatic disease. Asymptomatic patients with severe AS have excellent prognosis with conservative management and should not undergo surgery unless additional risk factors emerge. Early intervention in asymptomatic patients exposes them to operative risk and prosthetic valve complications without proven benefit. - **Initiation of high-dose statin therapy to slow progression of valve calcification**: Multiple randomized trials (SEAS, ASTRONOMER) have demonstrated that statins do NOT slow the progression of calcific aortic stenosis. While statins are indicated for other cardiovascular indications, they have no role in modifying the natural history of AS and should not be used as a primary strategy to delay intervention. - **Percutaneous balloon aortic valvuloplasty as definitive treatment**: Balloon aortic valvuloplasty has a high rate of restenosis (>50% at 6 months) and is rarely used in adults with native valve AS. It is reserved as a bridge to TAVR or surgical replacement in critically ill patients or those with contraindications to definitive intervention, not as a primary or definitive strategy in stable asymptomatic patients. **High-Yield:** Asymptomatic severe AS (AVA < 1.0 cm²) = watchful waiting with 6–12 monthly echo; surgery only if symptoms emerge, EF declines, or very high-risk features develop (AVA < 0.6, gradient > 80, velocity > 5 m/s). [cite: Harrison 21e Ch 263; ESC Valve Guidelines 2021]